EZH2: novel therapeutic target for human cancer

ASIAIR > College of Medical and Health Science > Department of Biotechnology > Journal Article > Item 310904400/86914

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/86914

Title:	EZH2: novel therapeutic target for human cancer
Authors:	李龍緣;Long-Yuan Li
Contributors:	生物科技學系
Keywords:	EZH2;Polycomb repressive;complex;Chromatin modification;Methylation
Date:	2014-03
Issue Date:	2014-11-07 06:49:35 (UTC+0)
Abstract:	Enhancer of Zeste homlog 2 (EZH2) is a catalytic subunit of epigenetic regulator Polycomb repressive complex 2 (PRC2), which trimethylates Lys 27 of histone H3, leading to silencing of the target genes that are involved in a variety of biological processes including tumor progression and stem cell maintenance. However, in addition to its canonical PRC2-dependent transcriptional repression function, EZH2 also acts as a gene activator in a noncanonical PRC2-independent manner. Overexpression of EZH2 has been detected in diverse cancers, and is associated with tumor malignancy. Moreover, activating mutations and inactivating mutations of EZH2 are also associated with certain types of cancer. Given EZH2’s multi-faceted function and role in cancer, context-specific strategy for targeting EZH2/EZH2-mediated signaling could serve as future targeted therapy/personalized medicine for human cancer.
Relation:	BioMedicine,4(1).
Appears in Collections:	[Department of Biotechnology] Journal Article

Files in This Item:

File	Size	Format
index.html	0Kb	HTML	302	View/Open